Jeffrey Arcara
Corporate Officer/Principal bei CORVUS PHARMACEUTICALS, INC.
Vermögen: - $ am 31.05.2024
Profil
Jeffrey S.
Arcara is currently the Chief Business Officer at Corvus Pharmaceuticals, Inc. He previously worked as the Vice President of Business Development at Neuromed Pharmaceuticals Ltd.
He completed his undergraduate degree at the University of Wisconsin and holds an MBA from UCLA Anderson School of Management.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 28.02.2024 | 0 ( -.--% ) | - $ | 31.05.2024 |
Aktive Positionen von Jeffrey Arcara
| Unternehmen | Position | Beginn |
|---|---|---|
| CORVUS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 06.02.2024 |
Ehemalige bekannte Positionen von Jeffrey Arcara
| Unternehmen | Position | Ende |
|---|---|---|
Neuromed Pharmaceuticals Ltd.
 Neuromed Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals Ltd. develops chronic pain drugs. Its NMED-1077 product is an extended release formulation of hydromorphone in phase 3 clinical development. It conducts research for drugs to cure anxiety, epilepsy, hypertension, and cardiovascular diseases. The company was founded by Dr. Terrance P. Snutch in 1998 and is headquartered in Vancouver, BC. | Corporate Officer/Principal | 27.01.2010 |
Ausbildung von Jeffrey Arcara
| University of Wisconsin | Undergraduate Degree |
| UCLA Anderson School of Management | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CORVUS PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Neuromed Pharmaceuticals Ltd.
Neuromed Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Neuromed Pharmaceuticals Ltd. develops chronic pain drugs. Its NMED-1077 product is an extended release formulation of hydromorphone in phase 3 clinical development. It conducts research for drugs to cure anxiety, epilepsy, hypertension, and cardiovascular diseases. The company was founded by Dr. Terrance P. Snutch in 1998 and is headquartered in Vancouver, BC. | Health Technology |
